Pomerantz Appointed Co-Lead Counsel in Akebia Therapeutics Securities Litigation

On May 27, 2022, U.S. Magistrate Judge Vera M. Scanlon of the Eastern District of New York appointed Pomerantz LLP as Co-Lead Counsel on behalf of Abraham Kiswani, the Co-Lead Plaintiff, and the class, in Deputy v. Akebia Therapeutics, Inc., 22-cv-1411 (E.D.N.Y.). This securities action alleges that Akebia Therapeutics, Inc. misled the market regarding the efficacy of its lead product, vadadustat, and overstated the regulatory and commercial prospects for the drug. Akebia is a biopharmaceutical company that focuses on the development and commercialization of therapeutics for patients suffering from kidney disease. The Company’s lead product…